Compositions and methods of treating cancer with glycomimetic peptides
AssigneeSusavion Biosciences, Inc.
InventorsLaura L. Eggink, J. Kenneth Hoober
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to pharmaceutical compositions comprising a peptide or multivalent polypeptide, and an anti-cancer agent. In some embodiments, the anti-cancer agent is conjugated to the peptide or multivalent polypeptide. The present disclosure also relates to a method of treating cancer or reducing cancer cell proliferation using the peptide or multivalent polypeptide. In some aspects, the peptide or multivalent polypeptide enhances the efficacy of the anti-cancer agent, the targeting of the anti-cancer agent to the cancer cells, or both.
Claims30
(canceled)
A pharmaceutical composition, comprising:
- a pharmaceutically acceptable carrier;
- an anti-cancer agent;
- and
- a therapeutic peptide, wherein the therapeutic peptide comprises:
- a sequence of X1-X2-X3-X4-X5-X6-X7-X8, or
- a construct having a central framework, a linker sequence, and at least two arms, wherein each arm consists of a core sequence of X1-X2-X3-X4-X5-X6-X7-X8, and each arm is linked to the central framework via the linker sequence,
- wherein
- X1 is H or N,
- X2 1 S P or Q,
- X3 1 S S or H,
- X4 is H, T, or L,
- X5 is P;
- or K, or is absent,
- X6 is R, L, or S, or is absent,
- X7 is S, or L, or is absent, and
- X8 is G or is absent.
5-6. (canceled)
10-11. (canceled)
14-15. (canceled)
18-25. (canceled)
27-32. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.